Related Experiment Video
Updated: Apr 25, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Integration of Time-Varying Pharmacometric Modeling With Cox Regression for Time-to-Event Analysis in NONMEM
Chih-Wei Lin1, Po-Wei Chen1, Sameer Doshi1
1Clinical Pharmacology, Modeling and Simulation, Amgen Inc, Thousand Oaks, California, USA.
This study introduces a novel semi-parametric method to analyze time-to-event data, accurately reflecting drug concentration changes over time. This approach improves pharmacokinetic/pharmacodynamic (PK/PD) analysis for time-to-event endpoints.
Area of Science:
- Pharmacometrics
- Statistical Modeling
- Drug Development
Background:
- Traditional time-to-event (TTE) analyses often use static drug exposure, ignoring real-world concentration variability.
- This limitation can lead to inaccurate pharmacokinetic (PK) or pharmacodynamic (PD) assessments for TTE endpoints.
Purpose of the Study:
- To develop and evaluate a methodology integrating time-varying pharmacometric models with Cox regression for TTE endpoints.
- To compare the performance of this semi-parametric approach against traditional parametric methods.
Main Methods:
- A simulation study was conducted using NONMEM software, incorporating a one-compartment PK model and a bathtub hazard function.
- The proposed semi-parametric method estimated parameters using partial likelihood via first-order approximation.
- Models were assessed using both static and time-varying exposure metrics.
Main Results:
- The semi-parametric method provided robust parameter estimates, especially when the baseline hazard was unknown.
- It demonstrated superior performance compared to parametric methods with incorrect baseline hazard assumptions.
- Utilizing time-varying exposure metrics significantly outperformed static metrics.
Conclusions:
- The proposed methodology effectively integrates time-varying PK/PD effects into TTE endpoint analysis.
- This flexible framework in NONMEM enhances model-informed decision-making for drug development, particularly for TTE outcomes.
Related Concept Videos
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Analysis of Population Pharmacokinetic Data
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

